Green Cross Health (GXH) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
27 Nov, 2025Executive summary
Operating revenue for the six months ended 30 September 2025 was $264.4m, up from $259.9m year-over-year.
Net profit after tax increased to $9.1m from $8.1m in the prior year period.
Basic earnings per share rose to 5.00 cents from 3.93 cents year-over-year.
Financial highlights
Operating profit before interest and tax was $17.5m, up from $16.1m year-over-year.
Total comprehensive income attributable to shareholders was $7.2m, with $1.9m to non-controlling interests.
Cash and cash equivalents at period end were $23.7m, down from $28.9m a year earlier.
Net cash inflow from operating activities was $21.6m, compared to $25.3m in the prior year.
Outlook and guidance
An interim dividend of 3.00 cents per share was declared, fully imputed, to be paid in December 2025.
Latest events from Green Cross Health
- Revenue up, profit down; network and loyalty programme expanded, with ongoing investments.GXH
AGM Presentation15 May 2026 - Revenue hit $523.8m, net profit $16.0m, and a 2.75c dividend was declared.GXH
H2 202515 May 2026 - Revenue and profit growth driven by acquisitions, innovation, and expanded clinical services.GXH
AGM Presentation15 May 2026 - Revenue up 2%, profit down 20% as inflation and lower COVID-19 activity hit margins.GXH
H2 202415 May 2026 - Revenue and profit rose as clinical services, digital innovation, and governance advanced.GXH
AGM 202516 Nov 2025 - Revenue, profit, and cash flow rose, with growth in both Pharmacy and Medical segments.GXH
H1 202513 Jun 2025